Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA Class II Alleles DRB111:01 and DQB103:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.

The AAPS journal - 21 May 2026

Rajendran Surendran, Gutierrez Andres H, Chien Ming-Shan, Tang Tracy, Gokemeijer Jochem, Forman Daron, De Groot Anne S, Jawa Vibha, Hamuro Lora

Abstract excerpt

Biologic combinations that modulate immune responses are increasingly used in oncology, enhancing anti-tumor immunity but also raising the risk of anti-drug antibody (ADA) development. Nivolumab administered in combination with ipilimumab results in significantly higher nivolumab ADA incidence (44%) compared to nivolumab monotherapy (12%). While previous analyses showed no clinical impact of nivolumab ADA on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to HLA-DQ beta-Chains

Share to HLA-DRB1 Chains

Share to Ipilimumab

Share to Melanoma

Share to Nivolumab

Source

Identifiers

PMID: 42162441
DOI: 10.1208/s12248-026-01244-9

Genes

ADA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.PMID 42162441Read ↗

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read ↗

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.Semantic proximity Read ↗

LncRNA antigens- a novel resource to improve immunotherapy efficacy predictions in MelanomaSemantic proximity Read ↗

LncRNA antigens - a novel resource to improve immunotherapy efficacy predictions in melanomaSemantic proximity Read ↗

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaSemantic proximity Read ↗

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read ↗

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.Semantic proximity Read ↗

Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility.Semantic proximity Read ↗

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity Read ↗

Allelic Variation in<i>HLA-DRB1</i>is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing<i>in Vitro</i>Semantic proximity Read ↗

Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.Semantic proximity Read ↗

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.